TY - JOUR
T1 - Comparative effects of vasodilator drugs on large and small coronary resistance vessels in the dog
AU - Forman, Robert
AU - Kirk, Edward S.
N1 - Funding Information:
Inc., perhexiline from Merrell-National Laboratories, verapamil from Knoll Pharmaceutical Company and nifedipine from Schering Corporation. These studies were supported in part by a grant from the National Institute of Health No. 23171-02.
PY - 1980/10
Y1 - 1980/10
N2 - Summary: One of the mechanisms whereby nitroglycerin is considered to reduce myocardial ischaemia and spasm is its preferential reduction of resistance of large compared with small coronary arteries. Accordingly, the action of nitroglycerin on these two resistance beds was compared with newer coronary vasodilator drugs. Following intracoronary administration of boluses of each drug, large and small vessel coronary resistance was measured in 14 dogs by recording the pressure drop across each vascular bed while flow was held constant. The dose of each drug was given to reduce small vessel resistance by 30% (range means 27 to 32%) which peaked at 5 to 10 s and declined to 8 to 18% at 1 min when reduction in large vessel resistance was at its maximum. At 1 min the large vessel resistance was decreased 56±5% by nitroglycerin, 23±5% by nitroprusside, 8±4% by perhexiline, 0±5% by verapamil and increased 8±5% by nifedipine. Nitroprusside reduced the large vessel resistance significantly less than nitroglycerin (P <0.001) for an equivalent reduction in small vessel resistance. Perhexiline, verapamil and nifedipine did not significantly reduce large vessel resistance and the discrepancy between these results and their antianginal and antispasm effect in humans was not apparent from these experiments. However, a suitable model of coronary spasm in the dog following ergonovine injection could not be created.
AB - Summary: One of the mechanisms whereby nitroglycerin is considered to reduce myocardial ischaemia and spasm is its preferential reduction of resistance of large compared with small coronary arteries. Accordingly, the action of nitroglycerin on these two resistance beds was compared with newer coronary vasodilator drugs. Following intracoronary administration of boluses of each drug, large and small vessel coronary resistance was measured in 14 dogs by recording the pressure drop across each vascular bed while flow was held constant. The dose of each drug was given to reduce small vessel resistance by 30% (range means 27 to 32%) which peaked at 5 to 10 s and declined to 8 to 18% at 1 min when reduction in large vessel resistance was at its maximum. At 1 min the large vessel resistance was decreased 56±5% by nitroglycerin, 23±5% by nitroprusside, 8±4% by perhexiline, 0±5% by verapamil and increased 8±5% by nifedipine. Nitroprusside reduced the large vessel resistance significantly less than nitroglycerin (P <0.001) for an equivalent reduction in small vessel resistance. Perhexiline, verapamil and nifedipine did not significantly reduce large vessel resistance and the discrepancy between these results and their antianginal and antispasm effect in humans was not apparent from these experiments. However, a suitable model of coronary spasm in the dog following ergonovine injection could not be created.
UR - http://www.scopus.com/inward/record.url?scp=0019195591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019195591&partnerID=8YFLogxK
U2 - 10.1093/cvr/14.10.601
DO - 10.1093/cvr/14.10.601
M3 - Review article
C2 - 6783305
AN - SCOPUS:0019195591
SN - 0008-6363
VL - 14
SP - 601
EP - 606
JO - Cardiovascular Research
JF - Cardiovascular Research
IS - 10
ER -